The covalent KRAS-G12C inhibitors (G12Ci) are rapidly changing the treatment landscape for advanced non-small cell lung cancer, but drug resistance remains a clinical challenge. Two recent studies have developed bispecific T cell engagers that form a link between T cells and tumor cells to selectively eliminate G12Ci-resistant cells.
Keywords: KRAS-G12C; bispecific T cell engagers.
© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.